An unusual cause of rhabdomyolysis in the patients with Parkinson’s disease: A report of two cases
Objective: To describe unusual cause of rhabdomyolysis in the two patients with Parkinson’s disease (PD). Background: Levodopa-induced dyskinesia (LID) is usually seen in advanced stage…Randomized, placebo-controlled, double-blind, two-period cross-over study to evaluate the safety, tolerability, and efficacy of a novel treatment combination for levodopa induced dyskinesia in Parkinson’s Disease (BUS-PD)
Objective: To evaluate the efficacy of buspirone in combination with amantadine in reducing levodopa-induced dyskinesia (LID) in patients with Parkinson’s disease (PD). Background: LID is…Shedding light on the relationship between dyskinesia assessed by a wearable device and impulsive compulsive behaviour in Parkinson’s disease
Objective: To evaluate the relationship between the presence of dyskinesia objectively detected using a wearable device and the presence of active and past impulsive compulsive…Neuroinflammation and activation of Zif-268 in dyskinetic 6-OHDA-lesioned rats is counteracted by association of a 5-HT1A/1B receptor agonist and an A2A receptor antagonist
Objective: To evaluate whether an early treatment with the serotonin 5-HT1A/1B receptor agonist eltoprazine and the adenosine A2A receptor antagonist preladenant prevent the onset of…Non-motor symptoms burden is greater in early Parkinson’s disease patients with motor complications
Objective: To analyze how motor complications are related to non-motor symptoms (NMS) burden in a population of early Parkinson´s disease (PD) patients. Background: It is…Analysis of the Shape of the Gocovri Steady-state PK Profile: Implications for an Extended Release Product
Objective: To demonstrate the unique shape and pharmacokinetic (PK) profile of Gocovri® (amantadine) extended release (ER) capsules by using metrics pertinent to ER dosage forms.…The effect of ADORA2A gene polymorphism on the dyskinesia of Parkinson’s Disease
Objective: To investigate the relationship of levodopa-induced dyskinesia with ADORA2A gene polymorphisms in PD patients. Background: With the progression of the disease, motor complications and…Dyskinesia Rates in Patients with Parkinson’s Disease on CVT-301 (levodopa inhalation powder)
Objective: Analysis of dyskinesia as reported by PD diary, adverse events, UPDRS part IV dyskinesia score and examiner rated observation, during a phase 3 study…Comparing motor and neuropathological features of Parkinson’s disease dementia and dementia with Lewy bodies
Objective: To compare motor and neuropathological features of Parkinson’s disease dementia (PDD) and dementia with Lewy bodies (DLB) and to determine clinical and neuropathological differences…Pharmacological effect of adenosine A2A receptor antagonist for levodopa-induced dyskinesia associated with cellular energy homeostasis
Objective: To evaluate the Levodopa induced dyskinesia (LID) in the clinical view point of autophagy and cellular energy homeostasis, and the pharmacological effect of adenosine…
- « Previous Page
- 1
- …
- 21
- 22
- 23
- 24
- 25
- …
- 44
- Next Page »